Literature DB >> 21243446

Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.

Daisy V Alapat1, Kenneth B Ain, David A Sloan, Kristin G Monaghan, Rouzan G Karabakhtsian.   

Abstract

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor of parafollicular or C-cells of thyroid that comprises 5-10% of all thyroid cancers [1, 2]. The neoplastic cells secrete calcitonin, carcinoembryonic antigen (CEA), and chromogranin A. Typically, increased serum levels of these tumor markers permit them to be used for initial diagnosis and long-term disease status surveillance. This article reports a case of sporadic MTC (pT2N0M0) in a young patient with normal serum tumor markers. A 16-year-old woman presented with MTC without evidence for this to be a familial case due to the absence of germline mutations in the RET proto-oncogene and negative family history. Surprisingly, there were normal preoperative serum levels of calcitonin, CEA, and chromogranin A, despite the immunohistochemistry showing strong and diffuse positive staining for these markers. This disparity between serum levels and tumor expression of calcitonin and CEA in MTC is quite rare. The relevant features of this case are discussed in consideration of the published experiences. This case may represent an unique subgroup of MTC with abnormal secretory capacity that requires reliance upon radiological evaluation for evidence of recurrent or disseminated disease, without the diagnostic benefit of serum tumor markers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21243446     DOI: 10.1007/s12020-010-9433-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  28 in total

1.  Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.

Authors:  J J Diez; P Iglesias
Journal:  Thyroid       Date:  2004-11       Impact factor: 6.568

2.  Metastatic neuroendocrine tumors to the thyroid gland mimicking medullary carcinoma: a pathologic and immunohistochemical study of six cases.

Authors:  X Matias-Guiu; J LaGuette; A M Puras-Gil; J Rosai
Journal:  Am J Surg Pathol       Date:  1997-07       Impact factor: 6.394

3.  Neuroendocrine tumor metastasis to the thyroid gland.

Authors:  Hiroko Yamada; Yasuhisa Hasegawa; Tetsuya Mitsudomi; Tsutomu Nakashima; Yasushi Yatabe
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

Review 4.  Current approaches to medullary thyroid carcinoma, sporadic and familial.

Authors:  Elizabeth A Fialkowski; Jeffrey F Moley
Journal:  J Surg Oncol       Date:  2006-12-15       Impact factor: 3.454

Review 5.  Medullary thyroid carcinoma--update and present management controversies.

Authors:  Mahir Al-Rawi; Malcolm H Wheeler
Journal:  Ann R Coll Surg Engl       Date:  2006-09       Impact factor: 1.891

6.  Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses.

Authors:  A H Redding; S N Levine; M R Fowler
Journal:  Thyroid       Date:  2000-10       Impact factor: 6.568

Review 7.  Recent advances in treatment of medullary thyroid carcinoma.

Authors:  D Vezzosi; A Bennet; P Caron
Journal:  Ann Endocrinol (Paris)       Date:  2007-03-27       Impact factor: 2.478

Review 8.  Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature.

Authors:  José Miguel Dora; Maria Heloisa Busi da Silva Canalli; Clarissa Capp; Márcia Khaled Puñales; José Gilberto H Vieira; Ana Luiza Maia
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

Review 9.  Thyroid cancer invasion of neck structures: epidemiology, evaluation, staging and management.

Authors:  Randall P Morton; Zahoor Ahmad
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2007-04       Impact factor: 2.064

10.  Serum calcitonin negative medullary thyroid carcinoma.

Authors:  Michael Sand; Marcos Gelos; Daniel Sand; Falk G Bechara; Gerd Bonhag; Ellen Welsing; Benno Mann
Journal:  World J Surg Oncol       Date:  2006-12-21       Impact factor: 2.754

View more
  9 in total

Review 1.  Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.

Authors:  Andrea Conway; Andres Wiernik; Ajay Rawal; Cornelius Lam; Hector Mesa
Journal:  Endocr Pathol       Date:  2012-06       Impact factor: 3.943

2.  True mixed medullary papillary carcinoma of the thyroid: a case report with low blood calcitonin levels.

Authors:  Pablo Zoroquiain; Javiera Torres; Ignacio Goñi; Lizzet Fernández; Antonieta Solar
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

Review 3.  Clinical challenges with calcitonin-negative medullary thyroid carcinoma.

Authors:  Maria Teresa Samà; Ruth Rossetto Giaccherino; Marco Gallo; Francesco Felicetti; Francesca Maletta; Nadia Bonelli; Alessandro Piovesan; Nicola Palestini; Ezio Ghigo; Emanuela Arvat
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-28       Impact factor: 4.553

Review 4.  Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.

Authors:  Maria Alevizaki; Elena Kyratzoglou; Aristoteles Bamias; Marinella Tzanela; Meletios A Dimopoulos; Katerina Saltiki
Journal:  Endocrine       Date:  2013-04-23       Impact factor: 3.633

5.  Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature.

Authors:  Huai-Jie Cai; Han Wang; Nan Cao; Bin Huang; Fan-Lei Kong; Li-Ren Lu; Ya-Yuan Huang; Wei Wang
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

6.  Unique Case of a Large Indolent Medullary Thyroid Carcinoma: Time to Reconsider the Medullary Thyroid Adenoma Entity?

Authors:  Simona Censi; Elisabetta Cavedon; Sara Watutantrige-Fernando; Susi Barollo; Loris Bertazza; Jacopo Manso; Maurizio Iacobone; Davide Nacamulli; Francesca Galuppini; Gianmaria Pennelli; Caterina Mian
Journal:  Eur Thyroid J       Date:  2018-12-06

7.  The Prognostic Impact of the Carcinoembryonic Antigen in Ampullary Cancer - A Retrospective Single Center Study.

Authors:  Hannah Fuellgraf; Oliver Schilling; Zon Weng Lai; Birte Kulemann; Sylvia Timme; Frank Makowiec; Jasmin H Shahinian; Jens Hoeppner; Martin Werner; Ulrich T Hopt; Ulrich F Wellner; Peter Bronsert
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

Review 8.  Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.

Authors:  Claudio Gambardella; Chiara Offi; Guglielmo Clarizia; Roberto Maria Romano; Immacolata Cozzolino; Marco Montella; Rosa Maria Di Crescenzo; Massimo Mascolo; Angelo Cangiano; Sergio Di Martino; Giancarlo Candela; Giovanni Docimo
Journal:  BMC Endocr Disord       Date:  2019-10-16       Impact factor: 2.763

9.  Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.

Authors:  Sun Jung Kim; Hyeok Jun Yun; Su-Jin Shin; Yong Sang Lee; Hang-Seok Chang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-05       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.